DPT and Confab Complete $10 Million Capital Investment

Article

The investment includes facility upgrades and expansion of development capabilities.

DPT Laboratories, a contract development and manufacturing organization (CDMO) specializing in semi-solid and liquid dosage forms, and Confab, a DPT company specializing in complex solids, semi-solids, and liquids, have completed a combined $10 million capital investment.

According to a press announcement from the company, DPT invested in a new compounding suite and upgrades to production filling lines. Additional upgrades include a remodeled front office area, enhanced security, and enhancement for further GMP compliance.

Confab, based in Montreal, made an investment to increase R&D capabilities with a new laboratory, new equipment, and expansion of its R&D team. According to a press announcement, Confab will now offer pharmaceutical development capabilities including formulation development, analytical method development, and technology transfers at commercial scale.

Source: DPT 

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Lee Cronin, founder and CEO of Chemify
Nicole Hunter, head of Global WMArchitect at Watson-Marlow Fluid Technology Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.